Bayer AG

Bayer stands ready to engage constructively with policymakers as the Made in Europe framework evolves. We support the political ambition to strengthen Europes industrial capacity and welcome European preference where public funding is involved.

Bayer welcomes and fully supports the European Commission's efforts to simplify and improve the EU rules for medical devices and in vitro diagnostics. We are pleased to provide feedback on the proposal for a regulation amending Regulations (EU) 2017/745 (MDR) and (EU) 2017/746 (IVDR). Our feedback includes identified issues and proposed solutions. Please find our feedback attached.

With over 160 years of experience, Bayer is a life science company and a global leader in healthcare, agriculture and nutrition. Driven by our mission,Health for all, Hunger for none, we harness the power of science to unlock new possibilities that enhance life while serving the most essential human needs.

Biotechnology has made enormous advances over the last years. It provides an entirely new approach, offering opportunities that were, a few decades ago, almost unimaginable. Biotechnologya sector that has flourished in other parts of the world and is largely lagging in Europe holds immense potential to tackle some of the EUs most pressing challenges.

Bayer welcomes the EU's commitment to strengthening competitiveness, resilience and leadership in key strategic technologies, including biotechnology. Biotech Act I marks an important step forward in supporting health biotech, and we must build on this to deliver a complete and comprehensive EU biotech framework.

Bayer appreciates the opportunity to contribute to the Call for evidence for an impact assessment Setting a renewable Energy Framework for the decade ahead. Bayer believes that renewable energy is important to mitigate climate change and meeting the EUs climate goals. Renewable biobased energy provides economic opportunities for farmers delivering existing and new crops to (new) renewable energy value chains.

At a Glance The convergence of science and technology has ushered in a new era of innovation in the life sciences. At Bayer, our mission of Health for All, Hunger for None drives our commitment to addressing societal and environmental needs through groundbreaking research in healthcare and agriculture. For Europe to remain globally competitive, innovative companies need a more coordinated and supportive framework.

Bayer appreciates the opportunity to contribute to the call for evidence for the European climate resilience and risk management initiative. Bayer is a company with core competencies in the life sciences, active in agricultural products and services, pharmaceuticals and consumer health products.

Bayer is investing significantly in plant breeding through its CropScience division, and released more than 400 new varieties worldwide in 2024, many of which in Europe in corn, oilseed rape and vegetables. Bayer is using, and is supportive of, the CPVR Regulation, but considers that it has not achieved all of the goals initially intended by the legislator, and that it would be necessary to strengthen certain…

Bayer's corporate mission Health for all - Hunger for none underscores the essential role that access to genetic resources plays in delivering innovations for health and food security. Bayer is fully committed to compliant access to genetic resources and supports the objectives of the Convention on Biological Diversity, the Nagoya Protocol, and Regulation (EU) 511/2014.